IPNY, Inc.

New York, Vereinigte Staaten von Amerika

Kontaktinformationen

420 Lexington Avenue, Suite 1756
New York NY 10170
Vereinigte Staaten von Amerika
Telefon: +1 212.488.4769
Webseite:

Tom Steadman

Tom Steadman

Managing Director

Telefon: 212-488-4774


Informationen

Hauptkompetenzen: Digital, Marketing Services, Direktmarketing / Telemarketing / Datenbankmarketing, Gesundheit, Finanzen

Gegründet in: 2012

Mitarbeiter: 30

Awards: 7

Kreative Projekte: 88

Kunden: 16

Hauptkompetenzen: Digital, Marketing Services, Direktmarketing / Telemarketing / Datenbankmarketing, Gesundheit, Finanzen

Gegründet in: 2012

Mitarbeiter: 30

Awards: 7

Kreative Projekte: 88

Kunden: 16

IPNY, Inc.

420 Lexington Avenue, Suite 1756
New York NY 10170
Vereinigte Staaten von Amerika
Telefon: +1 212.488.4769
Webseite:
Tom Steadman

Tom Steadman

Managing Director

Telefon: 212-488-4774

Fierce Pharma Marketing Awards Has Chosen The Finalists

IPNY and Regeneron Medical Affairs Insights & Value are recognized for their COVID campaign.

Fierce Pharma Marketing Awards has named IPNY and Regeneron Medical Affairs Insights & Value as a finalist in the PharmaTV category for their Mono WHAT? (Taking Aim Against COVID) campaign work.

The winners will be announced at the Awards Gala taking place on the evening of October 19, 2022 at the Philadelphia Academy of Fine Arts, during the annual Digital Pharma East conference. The Awards Gala will be an evening of celebration to honor the individuals, teams and companies who are leading the way in pharmaceutical marketing and advertising. See the finalist list here.

FiercePharma is a leading industry publication that delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry. They cover the pharma waterfront, from late-stage drug development through the entire lifecycle—tracking regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation, M&A deals and beyond. It is complete life sciences coverage from preclinical research to market and beyond.